BRAF and neoplasm: In Class II BRAF-mutant NCI-H2405 cells, while neither RMC-4550 nor RMC-6236 monotherapy had any impact on the parental or exarafenib-resistant line, combining either inhibitor with exarafenib produced an additional anti-tumor cell effect exclusively in the exarafenib-resistant cells, consistent with the observed upstream RAS activation (Fig. 6a and Supplementary Fig. 9a, 3rd and 4th row).